Breakthrough with cancer vaccine

July 09, 2020

Scientists are ready to trial a new cancer vaccine in humans following the successful outcome of their preclinical studies.

The new vaccine was developed by a Mater Research team based at The Translational Research Institute in collaboration with The University of Queensland.

Lead Researcher Associate Professor Kristen Radford says the vaccine has the potential to treat a variety of blood cancers and malignancies and is a major breakthrough for cancer vaccinations.

"We are hoping this vaccine could be used to treat blood cancers, such as myeloid leukaemia, non-Hodgkin's lymphoma, multiple myeloma, and paediatric leukaemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma," she said.

"Our new vaccine is comprised of human antibodies fused with tumour-specific protein, and we are investigating its capacity to target human cells while activating the memory of the tumour cells."

Associate Professor Radford says the vaccine offers several key advantages over existing cancer vaccines, which have already shown promise in early clinical trials.

"First, it can be produced as an 'off the shelf' clinical grade formulation, which circumvents the ?nancial and logistical issues associated with patient-specific vaccines," she said.

"Secondly, this prototype vaccine targets the key tumour cells required for the initiation of tumour-specific immune responses, thereby maximising potential effectiveness of treatment, while minimising potential side effects.

"We are very happy to see our research published in a prestigious journal, and we hope our continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future."
-end-
The study was published in the highly ranked journal, Clinical and Translational Immunology, and funded through grants from the Worldwide Cancer Research in the United Kingdom and the Mater Foundation.

Translational Research Institute

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.